Neurocrine Biosciences, Inc. (United States)

Neurocrine Biosciences is a biopharmaceutical company focused on neurological and endocrine disorders. Based in San Diego, the company developed Ingrezza (valbenazine), the first FDA-approved treatment for tardive dyskinesia, and Elagolix-based products Orilissa and Oriahnn for endometriosis and uterine fibroids. Neurocrine’s research targets movement disorders, psychiatric conditions, and hormone-related diseases.